Glucosum Pannonpharma

Glucosum Pannonpharma is a prescription‑only intravenous solution that contains glucose monohydrate as its active ingredient. It is supplied as a sterile solution for injection, formulated for parenteral nutrition and fluid replacement. Manufactured in the European Union, the product is classified as a carbohydrate (parenteral) drug and provides a rapid source of glucose when administered intravenously under medical supervision during acute care or peri‑operative periods to maintain energy balance.

Glucosum Pannonpharma is indicated for several acute clinical situations where rapid glucose delivery and precise fluid replacement are required to stabilize the patient.

- Treatment of hypoglycemia when oral glucose is not feasible. - Support of parenteral nutrition in patients unable to receive enteral feeding. - Fluid and electrolyte replacement during dehydration or surgical preparation. - Pre‑operative and post‑operative carbohydrate supplementation to reduce catabolism. - Management of electrolyte imbalances in conjunction with appropriate electrolyte solutions. - Adjunctive therapy for patients undergoing intensive care who require controlled glucose infusion rates.

The safety profile of Glucosum Pannonpharma reflects the typical reactions observed with intravenous glucose solutions, and most events are mild and self‑limiting.

Common: - Mild hyperglycemia that typically resolves after adjusting the infusion rate or concentration. - Transient nausea, vomiting, or mild headache that occurs during or shortly after the infusion. - Local irritation or mild pain at the injection site, sometimes accompanied by a temporary increase in serum osmolality.

Serious: - Severe hyperglycemia leading to osmotic diuresis, possible pulmonary edema, or cardiac arrhythmias. - Acute hypersensitivity reactions ranging from rash and itching to anaphylaxis. - Marked electrolyte disturbances such as significant hypokalemia or acute renal dysfunction secondary to osmotic diuresis.

When prescribing Glucosum Pannonpharma, clinicians should consider several precautionary measures to ensure safe administration.

- Assess blood glucose levels before initiation and monitor regularly during infusion. - Adjust dosage in patients with renal or hepatic impairment to avoid accumulation. - Use caution in individuals with a history of fluid overload, heart failure, or pulmonary edema. - Verify electrolyte status, especially potassium and sodium, prior to and during therapy. - Avoid rapid infusion rates that may cause sudden hyperglycemia or osmotic shifts. - Consider alternative carbohydrate sources for patients with known glucose intolerance or severe diabetes.

Glucosum Pannonpharma may interact with other agents that affect blood glucose, fluid balance, or electrolyte homeostasis.

Avoid: - Concurrent use of high‑dose insulin without adjusting the glucose infusion, which can precipitate severe hypoglycemia. - Co‑administration with other hypertonic glucose solutions, increasing the risk of hyperosmolar complications. - Simultaneous administration of potassium‑sparing diuretics, which may exacerbate hyperkalemia when combined with glucose‑induced shifts.

Use with caution: - Diuretics that promote electrolyte loss; monitor potassium and sodium levels closely. - Medications that cause fluid retention, such as corticosteroids or certain antihypertensives. - Catecholamine vasopressors, which can elevate blood glucose and mask hyperglycemia from the infusion. - Renal replacement therapies (hemodialysis or hemofiltration) that alter glucose clearance; adjust infusion rates accordingly.